Ju Chao Zi Xun·2025-12-02 13:47Core Viewpoint - The company announced a strategic shift by divesting its stake in the subsidiary Lingzhi Yunchuang Technology Co., Ltd. to focus on its core optical business, moving away from the wheel-based medical service and logistics delivery robot sector [2][3]. Group 1: Transaction Details - The transaction consists of two parts: a share transfer and a capital increase, which are interdependent [2]. - The share transfer involves the full subsidiary Lianyi Helite Technology Co., Ltd. selling its stake in Lingzhi Yunchuang, with a transfer price of 14.3 million yuan for a registered capital of 5.6746 million yuan [2]. - Following the capital increase, the registered capital of Lingzhi Yunchuang will rise from 10 million yuan to 12.36 million yuan, with Lianyi Helite's ownership dropping from 100% to 34.9951%, while Wan Ce Zhizao will hold 65.0049% [2]. Group 2: Business Transition - Post-transaction, the company will transfer all non-Lingzhi Yunchuang medical robot-related R&D results, design materials, intellectual property, unfulfilled contracts, and customer relationships to Lingzhi Yunchuang [3]. - Lingzhi Yunchuang, established on May 11, 2024, has a registered capital of 10 million yuan and focuses on the development and sales of intelligent robots, particularly in the medical service and logistics sectors [3]. Group 3: Financial Performance - Lingzhi Yunchuang has reported losses in recent years, with 2024 revenues of 206,200 yuan and a net loss of 3.2282 million yuan, resulting in total assets of 4.466 million yuan and a net asset deficit of 938,200 yuan [3]. - For the period from January to July 2025, Lingzhi Yunchuang generated revenues of 152,480 yuan and a net loss of 623,920 yuan, with total assets of 7.514 million yuan and a net asset deficit of 597,400 yuan as of July 31 [3]. Group 4: Legal and Ownership Status - As of the announcement date, Lingzhi Yunchuang's ownership is clear, with no pledges or restrictions on rights, and it does not involve any major disputes [4].